Asia Pacific Biodefense Market Size, Share, Forecast, and Growth Opportunity

Asia Pacific biodefense market will grow by 7.8% annually over 2020-2030 with a total addressable market cap of $15.8 billion in the fast-growing region despite the COVID-19 impact.
Highlighted with 32 tables and 40 figures, this 108-page report “Asia Pacific Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces
    The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country.
    Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
    Vaccines
  • Anthrax
  • Smallpox
  • Botulism
  • Nuclear/Radiation
  • E-Bola
  • Zika
  • Other Vaccines
    Biothreat Detection Devices
  • Detectors/Triggering Devices
  • Assays and Reagents
  • Samplers
  • Identifiers
    Antibiotics
    Masks
    Other Products
    Based on Sales Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Online Sales
  • Offline Sales
    Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Military
  • Civilian
    Geographically, the following national/local markets are fully investigated:
  • Japan
  • China
  • South Korea
  • Australia
  • India
  • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
    For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.
    The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
    Specifically, potential risks associated with investing in Asia Pacific biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
    Key Players (this may not be a complete list and extra companies can be added upon request):
    Achaogen, Inc.
    Alexeter Technologies LLC
    Alnylam Pharmaceuticals, Inc.
    Altimmune, Inc.
    Bavarian Nordic AS
    BioFactura, Inc.
    Cleveland Biolabs, Inc.
    Dynavax Technologies Inc
    Dynport Vaccine Company LLC (DVC)
    Elusys Therapeutics, Inc.
    Emergent BioSolutions Inc
    General Dynamics Corp.
    GlaxoSmithKline Plc
    Ichor Medical Systems
    Mediimmune (AstraZeneca)
    Nanotherapeutics, Inc.
    Ology Bioscience
    PathSensors Inc
    Pluristem Therapeutics
    Sanofi Pasteur Ltd.
    SIGA Technologies, Inc.
    Soligenix, Inc.
    Xoma Corporation
    (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
    For Sample Report Visit Here: https://www.rightsightresearch.com/reports/asia-pacific-biodefense-market/rsr-5c5a99b

Leave a Comment